13F Holdings
中文EN

TRVI Trevi Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1563880 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY-8.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-24.7%
ROA-23.8%
ROIC (approx.)-27.2%
Asset turnover—

Leverage & solvency

Liabilities / assets2.6%
Debt / equity0.00x
Current ratio38.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$33.48M$39.38M$23.68M$19.83M$22.98M
SG&A expense$15.85M$12.15M$10.24M$10.07M$9.49M
Operating income-$49.33M-$51.52M-$33.92M-$29.91M-$32.48M
Interest expense$0$4,000$391,000$1.16M$1.20M
Pretax income-$42.82M-$47.94M-$29.10M-$29.19M-$33.96M
Income tax-$64,000-$30,000-$32,000-$36,000-$21,000
Net income-$42.76M-$47.91M-$29.07M-$29.15M-$33.94M
EBITDA-$49.18M-$51.38M-$33.80M-$29.86M-$32.43M
EPS (basic)-0.32-0.47-0.29-0.45-1.49
EPS (diluted)-0.32-0.47-0.29-0.45-1.49
Weighted avg. shares (diluted)134.75M101.97M99.03M64.54M22.84M
Balance sheet
Cash & equivalents$18.91M$34.10M$32.40M$12.59M$36.83M
Short-term investments$169.35M$73.53M$50.57M$107.92M—
Current assets$191.66M$109.43M$87.55M$122.62M$37.96M
PP&E, net$178,000$157,000$216,000$170,000$53,000
Total assets$193.44M$110.90M$89.40M$123.02M$38.48M
Current liabilities$9.75M$10.51M$5.82M$13.40M$12.72M
Total liabilities$10.20M$11.26M$6.86M$15.56M$21.40M
Shareholders' equity$183.24M$99.64M$82.55M$107.46M$17.07M
Shares outstanding128.31M93.60M68.28M59.94M28.51M
Cash flow statement
Operating cash flow-$42.09M-$38.26M-$31.71M-$28.18M-$28.95M
Capital expenditure$12,000$35,000$137,000$159,000—
Free cash flow-$42.10M-$38.29M-$31.85M-$28.33M—
Investing cash flow-$94.11M-$21.53M$59.43M-$107.37M—
Financing cash flow$121.01M$61.48M-$7.91M$111.31M$20.77M
Depreciation & amortization$144,000$147,000$123,000$43,000$50,000
Stock-based compensation$5.18M$3.59M$2.25M$2.33M$2.54M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.